SB 007
Alternative Names: SB-007Latest Information Update: 17 Dec 2024
Price :
$50 *
At a glance
- Originator Splice Bio
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action ABCA4 protein modulators; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Stargardt disease
Most Recent Events
- 12 Dec 2024 US FDA approves IND application for SB 007 in Stargardt Disease
- 12 Dec 2024 SpliceBio plans a phase I/II ASTRA trial for Stargardt disease in the first half of 2025
- 05 Mar 2024 Preclinical trials in Stargardt disease in Spain (Parenteral), prior to March 2024 (SpliceBio pipeline, March 2024)